<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00587834</url>
  </required_header>
  <id_info>
    <org_study_id>06-PER-002-CTX</org_study_id>
    <nct_id>NCT00587834</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration</brief_title>
  <official_title>A Clinical Trial to Evaluate Gintuit (TM) (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen) as an Alternative to Tissue From the Palate to Enhance Oral Soft Tissue Regeneration and Wound Healing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Organogenesis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Organogenesis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate Gintuit as a safe and effective alternative to
      palatal tissue in the treatment of subjects (with recession-type defects) who have an
      insufficient zone of attached gingiva associated with at least two nonadjacent teeth.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With at Least 2 mm Keratinized Tissue (KT) at 6 Months at the Gintuit Treated Site.</measure>
    <time_frame>6 months</time_frame>
    <description>The superiority of Gintuit relative to a pre-defined standard (50% success) for a 2 mm KT threshold after six months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Color Same as Adjacent Tissues After 6 Months (Superiority)</measure>
    <time_frame>6 months</time_frame>
    <description>An examiner assessed color of both treated sites compared with the adjacent, non-treated tissue. The assessment was recorded as &quot;More Red&quot;, &quot;Equally Red&quot;, or &quot;Less Red&quot; as compared to adjacent, non-treated tissue. A match in color with the surrounding tissue is considered a positive aesthetic outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Texture Same as Adjacent Tissues After 6 Months (Superiority)</measure>
    <time_frame>6 months</time_frame>
    <description>An examiner assessed texture of both treated sites compared with the adjacent, non-treated tissue. The assessment was recorded as &quot;More Firm&quot;, &quot;Equally Firm&quot;, or &quot;Less Firm&quot; as compared to adjacent, non-treated tissue. A match in texture with the surrounding tissue is considered a positive aesthetic outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With at Least 1 mm Keratinized Tissue (KT) at 6 Months at the Gintuit Treated Site.</measure>
    <time_frame>6 months</time_frame>
    <description>The superiority of Gintuit relative to a pre-defined standard (80% success) for a 1 mm KT threshold after six months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Preference After 6 Months/Early Termination (Superiority)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients expressing preference for Gintuit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Site Sensitivity Mild or Absent After 1 Week(Superiority)</measure>
    <time_frame>6 months</time_frame>
    <description>The sensitivity of Gintuit, Free Gingival Graft (FGG) and palatal donation sites was assessed with a puff of air and rated by the Investigator as none, mild, moderate or severe sensitivity. The sensitivity of Control was determined as the most sensitive of FGG and palatal donation sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Absent After 3 Days (Superiority)</measure>
    <time_frame>Day 3</time_frame>
    <description>Pain Assessment(Modified Intent-to-Treat Population)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Gingival Recession</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within-subject design: one side of the mouth receives Gintuit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Within-subject control: one side of mouth receives tissue harvested from the palate</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gintuit</intervention_name>
    <description>Application of Gintuit at Day 0 to the gingival bed</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous palatal tissue</intervention_name>
    <description>Tissue will be harvested from the subject's palate and placed on the gingival bed</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is at least 18 years of age but no more than 70 years of age.

          -  Subject has at least two non-adjacent teeth in contralateral quadrants of the same jaw
             with an insufficient zone (&lt; or = 1mm) of attached gingiva that requires soft tissue
             grafting. (1-3 teeth may be treated. In case of adjacent teeth requiring grafting,
             only one tooth at each site will act as test or control tooth, but all teeth will get
             the same treatment).

          -  Root coverage is not desired at the time of grafting.

          -  Females of childbearing potential must have a documented negative urine pregnancy
             test.

          -  Subjects must have read, understood and signed an institutional review board (IRB)
             approved Informed Consent Form.

          -  Subjects must be able and willing to follow study procedures and instructions.

        Exclusion Criteria:

          -  Subject with class III recession in the presence of a shallow vestibule or class IV
             recession.

          -  Subject with vestibule depth of less than 7mm from base of recession.

          -  Subject with any systemic conditions that could compromise wound healing and preclude
             periodontal surgery (i.e., diabetes mellitus, cancer, human immunodeficiency virus
             (HIV), bone metabolic diseases).

          -  Subject who is currently receiving or has received within two months prior to study
             entry, systemic corticosteroids, immunosuppressive agents, radiation therapy, and/or
             chemotherapy which could compromise wound healing and preclude periodontal surgery.

          -  Subject with the presence of acute infectious lesions in the areas intended for
             surgery.

          -  Subject who has used any tobacco product within 3 months.

          -  Subject who is taking intramuscular or intravenous bisphosphonates.

          -  Subject with only molar teeth suitable for soft tissue grafting.

          -  Subject with teeth that have Miller Grade 2 or higher mobility.

          -  Subject with known hypersensitivity to bovine collagen and/or iodine (shellfish
             allergy).

          -  Subject who has received an investigational drug or biological/bioactive treatment
             within 30 days prior to study enrollment (medical or dental).

          -  Subject who was previously treated with Gintuit, Dermagraft or any other skin graft at
             the target site(s) or immediately adjacent teeth.

          -  Subject, who in the opinion of the investigator, for any reason other than those
             listed above, will not be able to complete the study per protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael McGuire, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Perio Health Professionals, PLLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nevins Perio, LLC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Center for Oral Health Research</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perio Health Professionals, PLLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>McGuire MK, Scheyer ET, Nevins ML, Neiva R, Cochran DL, Mellonig JT, Giannobile WV, Bates D. Living cellular construct for increasing the width of keratinized gingiva: results from a randomized, within-patient, controlled trial. J Periodontol. 2011 Oct;82(10):1414-23. doi: 10.1902/jop.2011.100671. Epub 2011 Mar 29.</citation>
    <PMID>21513473</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2008</study_first_posted>
  <results_first_submitted>April 4, 2012</results_first_submitted>
  <results_first_submitted_qc>October 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 8, 2012</results_first_posted>
  <disposition_first_submitted>January 22, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>January 22, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 15, 2010</disposition_first_posted>
  <last_update_submitted>October 9, 2012</last_update_submitted>
  <last_update_submitted_qc>October 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gingival Recession</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gintuit and Autologous Free Gingival Graft (FGG)</title>
          <description>Single application of Gintuit and FGG (control); split-mouth design</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gintuit and Autologous Free Gingival Graft (FGG)</title>
          <description>Single application of Gintuit and FGG (control); split-mouth design</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.14" spread="13.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With at Least 2 mm Keratinized Tissue (KT) at 6 Months at the Gintuit Treated Site.</title>
        <description>The superiority of Gintuit relative to a pre-defined standard (50% success) for a 2 mm KT threshold after six months.</description>
        <time_frame>6 months</time_frame>
        <population>Per protocol the first 2 subjects per Investigator were training subjects and evaluated for safety only. There were 11 training subjects and the remaining 85 subjects were analyzed for all efficacy outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Gintuit</title>
            <description>Single application;split-mouth design</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 2 mm Keratinized Tissue (KT) at 6 Months at the Gintuit Treated Site.</title>
          <description>The superiority of Gintuit relative to a pre-defined standard (50% success) for a 2 mm KT threshold after six months.</description>
          <population>Per protocol the first 2 subjects per Investigator were training subjects and evaluated for safety only. There were 11 training subjects and the remaining 85 subjects were analyzed for all efficacy outcomes.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" lower_limit="88.4" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Superiority relative to a pre-defined standard (50% success)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Exact Bionomial Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Color Same as Adjacent Tissues After 6 Months (Superiority)</title>
        <description>An examiner assessed color of both treated sites compared with the adjacent, non-treated tissue. The assessment was recorded as “More Red”, “Equally Red”, or “Less Red” as compared to adjacent, non-treated tissue. A match in color with the surrounding tissue is considered a positive aesthetic outcome.</description>
        <time_frame>6 months</time_frame>
        <population>See description in primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Gintuit Equally Red as Adjacent Tissue</title>
          </group>
          <group group_id="O2">
            <title>Gintuit Not Equally Red as Adjacent Tissue</title>
            <description>Not Equally Red includes responses of &quot;more red&quot; and &quot;less red&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Color Same as Adjacent Tissues After 6 Months (Superiority)</title>
          <description>An examiner assessed color of both treated sites compared with the adjacent, non-treated tissue. The assessment was recorded as “More Red”, “Equally Red”, or “Less Red” as compared to adjacent, non-treated tissue. A match in color with the surrounding tissue is considered a positive aesthetic outcome.</description>
          <population>See description in primary outcome measure.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Control Equally Red as Adjacent Tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Control Not Equally Red as Adjacent Tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Compare participants with (1) Gintuit equally red and Control not equally red to (2) Gintuit not equally red and Control equally red</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Texture Same as Adjacent Tissues After 6 Months (Superiority)</title>
        <description>An examiner assessed texture of both treated sites compared with the adjacent, non-treated tissue. The assessment was recorded as “More Firm”, “Equally Firm”, or “Less Firm” as compared to adjacent, non-treated tissue. A match in texture with the surrounding tissue is considered a positive aesthetic outcome.</description>
        <time_frame>6 months</time_frame>
        <population>See description in primary outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Gintuit Equally Firm as Adjacent Tissue</title>
          </group>
          <group group_id="O2">
            <title>Gintuit Not Equally Firm as Adjacent Tissue</title>
            <description>Not Equally Firm includes responses of &quot;less firm&quot; and &quot;more firm&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Texture Same as Adjacent Tissues After 6 Months (Superiority)</title>
          <description>An examiner assessed texture of both treated sites compared with the adjacent, non-treated tissue. The assessment was recorded as “More Firm”, “Equally Firm”, or “Less Firm” as compared to adjacent, non-treated tissue. A match in texture with the surrounding tissue is considered a positive aesthetic outcome.</description>
          <population>See description in primary outcome measures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Control Equally Firm as Adjacent Tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Control Not Equally Firm as Adjacent Tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Compare participants with (1)Gintuit equally firm and Control not equally firm to (2) Gintuit not equally firm and Control equally firm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With at Least 1 mm Keratinized Tissue (KT) at 6 Months at the Gintuit Treated Site.</title>
        <description>The superiority of Gintuit relative to a pre-defined standard (80% success) for a 1 mm KT threshold after six months.</description>
        <time_frame>6 months</time_frame>
        <population>See description in primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Gintuit</title>
            <description>Single application;split-mouth design</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 1 mm Keratinized Tissue (KT) at 6 Months at the Gintuit Treated Site.</title>
          <description>The superiority of Gintuit relative to a pre-defined standard (80% success) for a 1 mm KT threshold after six months.</description>
          <population>See description in primary outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Superiority relative to a pre-defined threshold (80%) success</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Exact binomial test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Preference After 6 Months/Early Termination (Superiority)</title>
        <description>Number of patients expressing preference for Gintuit.</description>
        <time_frame>6 months</time_frame>
        <population>See description in primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Gintuit</title>
            <description>Single application of Gintuit and FGG (control); split-mouth design. Number of subjects preferring Gintuit over Control.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Preference After 6 Months/Early Termination (Superiority)</title>
          <description>Number of patients expressing preference for Gintuit.</description>
          <population>See description in primary outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="61.0" upper_limit="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The proportion of Gintuit as the preferred procedure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Exact binomial test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgical Site Sensitivity Mild or Absent After 1 Week(Superiority)</title>
        <description>The sensitivity of Gintuit, Free Gingival Graft (FGG) and palatal donation sites was assessed with a puff of air and rated by the Investigator as none, mild, moderate or severe sensitivity. The sensitivity of Control was determined as the most sensitive of FGG and palatal donation sites.</description>
        <time_frame>6 months</time_frame>
        <population>See description in primary outcome measures. The presence of Coe-Pak (protective periodontal dressing) at Week 1 prohibited the assessment of sensitivity for 14 subjects. The analysis was performed on 71 of the 85 subjects evaluated for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Gintuit Not Sensitive</title>
            <description>Included ratings of None and Mild</description>
          </group>
          <group group_id="O2">
            <title>Gintuit Sensitive</title>
            <description>Included ratings of Moderate and Severe</description>
          </group>
        </group_list>
        <measure>
          <title>Surgical Site Sensitivity Mild or Absent After 1 Week(Superiority)</title>
          <description>The sensitivity of Gintuit, Free Gingival Graft (FGG) and palatal donation sites was assessed with a puff of air and rated by the Investigator as none, mild, moderate or severe sensitivity. The sensitivity of Control was determined as the most sensitive of FGG and palatal donation sites.</description>
          <population>See description in primary outcome measures. The presence of Coe-Pak (protective periodontal dressing) at Week 1 prohibited the assessment of sensitivity for 14 subjects. The analysis was performed on 71 of the 85 subjects evaluated for efficacy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Control Not Sensitive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Control Sensitive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Compare participants with (1) Gintuit not sensitive and Control sensitive to (2) Gintuit sensitive and Control not sensitive.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3173</p_value>
            <method>McNemar</method>
            <method_desc>McNemar's paired comparison test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Absent After 3 Days (Superiority)</title>
        <description>Pain Assessment(Modified Intent-to-Treat Population)</description>
        <time_frame>Day 3</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gintuit</title>
          <description>Adverse events occurring at the Gintuit treated site</description>
        </group>
        <group group_id="E2">
          <title>Free Gingival Graft</title>
          <description>Adverse events occurring at the autologous free gingival graft site</description>
        </group>
        <group group_id="E3">
          <title>Palatal Donation Site</title>
          <description>Adverse events occurring at the palatal donation site</description>
        </group>
        <group group_id="E4">
          <title>Mouth</title>
          <description>Adverse events occurring in the mouth and not localized to the Gintuit, FGG, or palatal donation sites.</description>
        </group>
        <group group_id="E5">
          <title>Other</title>
          <description>Adverse events occurring at any other location in the body or systemic conditions</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pains</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant Metastatic Fibrous Histiocytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review communications prior to public release and can embargo communications regarding trial results for at least 30 days in advance of public release. The sponsor can request removal of any confidential or proprietary information provided by sponsor and extend such review period for another 90 days to file patent applications or take other steps to protect the sponsor's intellectual property interests.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Secondary outcome measures were tested with a closed testing strategy; therefore pain was not tested (no p-value) because previous endpoint (site sensitivity) failed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director of Clinical Operations</name_or_title>
      <organization>Organogenesis Inc.</organization>
      <phone>781-575-0775</phone>
      <email>clinical@organo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

